Skip to main content
Top
Published in: Endocrine 1/2013

01-02-2013 | Original Article

Association between chronic hepatitis C virus infection and high levels of circulating N-terminal pro-brain natriuretic peptide

Authors: Kyoko Okada, Norihiro Furusyo, Eiichi Ogawa, Hiroaki Ikezaki, Tsuyoshi Ihara, Takeo Hayashi, Mosaburo Kainuma, Masayuki Murata, Jun Hayashi

Published in: Endocrine | Issue 1/2013

Login to get access

Abstract

The association between HCV infection and myocardial disorders remains unclear. This study aimed to assess whether or not HCV infection influences myocardial dysfunction by the use of NT-proBNP, a sensitive marker of myocardial dysfunction. A total of 198 participants [99 patients with chronic HCV infection (aged 46–68 years) and 99 anti-HCV-negative sex and age matched controls] were examined. Serum HCV-RNA level and HCV genotype were tested and liver biopsy was done only for the patient group. The NT-proBNP concentration of the HCV patients (mean 71.6 ± 79.1 pg/ml; median 46.0 pg/ml, range 5.0–400.0) was significantly higher than that of the controls (mean 39.8 ± 24.4 pg/ml; median 35.8 pg/ml, range 7.0–108.0) (P < 0.05). 20.0 % of the HCV patients and 0.6 % of the controls had high NT-proBNP (higher than 125 pg/ml; the single cut off point for patients under 75 years of age) (P < 0.05). Stepwise multiple regression analysis revealed that chronic HCV infection was independently correlated with NT-proBNP level after adjustment for parameters that might influence NT-proBNP (P = 0.005). Our data suggest that chronic HCV infection is associated with increased NT-proBNP, indicating that chronic HCV infection might induce myocardial dysfunction.
Literature
1.
go back to reference R.J. Johnson, D.R. Gretch, H. Yamabe et al., Membranoproliferative glomerulonephritis associated with hepatitis C virus infection in the United States, 1998 through 1994. N. Engl. J. Med. 341, 556–562 (1999)CrossRef R.J. Johnson, D.R. Gretch, H. Yamabe et al., Membranoproliferative glomerulonephritis associated with hepatitis C virus infection in the United States, 1998 through 1994. N. Engl. J. Med. 341, 556–562 (1999)CrossRef
2.
go back to reference H.B. El-Serag, H. Hampel, C. Yeh, L. Rabeneck, Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 36, 1439–1445 (2002)PubMed H.B. El-Serag, H. Hampel, C. Yeh, L. Rabeneck, Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 36, 1439–1445 (2002)PubMed
3.
go back to reference P. Cacoub, C. Renou, E. Rosenthal et al., Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. Medicine (Baltim.) 79, 47–56 (2000)CrossRef P. Cacoub, C. Renou, E. Rosenthal et al., Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. Medicine (Baltim.) 79, 47–56 (2000)CrossRef
4.
go back to reference A. Matsumori, Y. Matoba, S. Sasayama, Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation 92, 2519–2525 (1995)PubMedCrossRef A. Matsumori, Y. Matoba, S. Sasayama, Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation 92, 2519–2525 (1995)PubMedCrossRef
5.
go back to reference M. Okabe, K. Fukuda, K. Arakawa et al., Chronic variant of myocarditis associated with hepatitis C virus infection. Circulation 96, 22–24 (1997)PubMedCrossRef M. Okabe, K. Fukuda, K. Arakawa et al., Chronic variant of myocarditis associated with hepatitis C virus infection. Circulation 96, 22–24 (1997)PubMedCrossRef
6.
go back to reference G. Palladini, C. Campana, C. Klersy et al., Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107, 2440–2445 (2003)PubMedCrossRef G. Palladini, C. Campana, C. Klersy et al., Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107, 2440–2445 (2003)PubMedCrossRef
7.
go back to reference T.J. Wang, M.G. Larson, D. Levy et al., Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N. Engl. J. Med. 350, 655–663 (2004)PubMedCrossRef T.J. Wang, M.G. Larson, D. Levy et al., Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N. Engl. J. Med. 350, 655–663 (2004)PubMedCrossRef
8.
go back to reference A. Matsumori, T. Shimada, N.M. Chapman et al., Myocarditis and heart failure associated with hepatitis C virus infection. J. Card. Fail. 12, 293–298 (2006)PubMedCrossRef A. Matsumori, T. Shimada, N.M. Chapman et al., Myocarditis and heart failure associated with hepatitis C virus infection. J. Card. Fail. 12, 293–298 (2006)PubMedCrossRef
9.
go back to reference A. Antonelli, C. Ferri, S.M. Ferrari, S. Marchi et al., N-terminal pro-brain natriuretic peptide and tumor necrosis factor-alpha both are increased in patients with hepatitis C. J. Interferon Cytokine Res. 30, 359–363 (2010)PubMedCrossRef A. Antonelli, C. Ferri, S.M. Ferrari, S. Marchi et al., N-terminal pro-brain natriuretic peptide and tumor necrosis factor-alpha both are increased in patients with hepatitis C. J. Interferon Cytokine Res. 30, 359–363 (2010)PubMedCrossRef
10.
go back to reference A. Zaphiriou, S. Robb, T. Murray-Thomas et al., The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur. J. Heart Fail. 7, 537–541 (2005)PubMedCrossRef A. Zaphiriou, S. Robb, T. Murray-Thomas et al., The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur. J. Heart Fail. 7, 537–541 (2005)PubMedCrossRef
11.
go back to reference J.L. Januzzi Jr., C.A. Camargo, S. Anwaruddin et al., The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am. J. Cardiol. 95, 948–954 (2005)PubMedCrossRef J.L. Januzzi Jr., C.A. Camargo, S. Anwaruddin et al., The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am. J. Cardiol. 95, 948–954 (2005)PubMedCrossRef
12.
go back to reference The Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetol. Int. 1, 2–20 (2010) The Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetol. Int. 1, 2–20 (2010)
13.
go back to reference J. Hayashi, Y. Kishihara, K. Yamaji et al., Hepatitis C viral quasi species and liver damage in patients with chronic hepatitis C virus infection. Hepatology 25, 697–701 (1997)PubMedCrossRef J. Hayashi, Y. Kishihara, K. Yamaji et al., Hepatitis C viral quasi species and liver damage in patients with chronic hepatitis C virus infection. Hepatology 25, 697–701 (1997)PubMedCrossRef
14.
go back to reference J. Hayashi, N. Furusyo, I. Ariyama et al., A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia. J. Infect. Dis. 181, 1523–1527 (2000)PubMedCrossRef J. Hayashi, N. Furusyo, I. Ariyama et al., A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia. J. Infect. Dis. 181, 1523–1527 (2000)PubMedCrossRef
15.
go back to reference N. Furusyo, M. Katoh, Y. Tanabe et al., Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group. World J. Gastroenterol. 12, 784–790 (2006)PubMed N. Furusyo, M. Katoh, Y. Tanabe et al., Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group. World J. Gastroenterol. 12, 784–790 (2006)PubMed
16.
go back to reference K. Okada, N. Maeda, M. Tatsukawa et al., The influence of lifestyle modification on carotid artery intima-media thickness in a suburban Japanese population. Atherosclerosis 173, 329–337 (2004)PubMedCrossRef K. Okada, N. Maeda, M. Tatsukawa et al., The influence of lifestyle modification on carotid artery intima-media thickness in a suburban Japanese population. Atherosclerosis 173, 329–337 (2004)PubMedCrossRef
17.
go back to reference M. Emoto, Y. Nishizawa, K. Maekawa et al., Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 22, 818–822 (1999)PubMedCrossRef M. Emoto, Y. Nishizawa, K. Maekawa et al., Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 22, 818–822 (1999)PubMedCrossRef
18.
go back to reference H. Mahrholdt, A. Wagner, C.C. Deluigi et al., Presentation, patterns of myocardial image, and clinical course of viral myocarditis. Circulation 114, 1581–1590 (2006)PubMedCrossRef H. Mahrholdt, A. Wagner, C.C. Deluigi et al., Presentation, patterns of myocardial image, and clinical course of viral myocarditis. Circulation 114, 1581–1590 (2006)PubMedCrossRef
19.
go back to reference A. Frustaci, C. Chimenti, F. Calabrese et al., Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 107, 857–863 (2003)PubMedCrossRef A. Frustaci, C. Chimenti, F. Calabrese et al., Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 107, 857–863 (2003)PubMedCrossRef
20.
go back to reference K.L. Baughman, Diagnosis of myocarditis: death of Dallas criteria. Circulation 113, 593–595 (2006)PubMedCrossRef K.L. Baughman, Diagnosis of myocarditis: death of Dallas criteria. Circulation 113, 593–595 (2006)PubMedCrossRef
21.
go back to reference R.E. Eckart, S.S. Love, J.E. Atwood et al., Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J. Am. Coll. Cardiol. 44, 201–205 (2004)PubMedCrossRef R.E. Eckart, S.S. Love, J.E. Atwood et al., Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J. Am. Coll. Cardiol. 44, 201–205 (2004)PubMedCrossRef
22.
go back to reference T.A. McDonagh, A.D. Cunningham, C.E. Morrison et al., Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 86, 21–26 (2001)PubMedCrossRef T.A. McDonagh, A.D. Cunningham, C.E. Morrison et al., Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 86, 21–26 (2001)PubMedCrossRef
Metadata
Title
Association between chronic hepatitis C virus infection and high levels of circulating N-terminal pro-brain natriuretic peptide
Authors
Kyoko Okada
Norihiro Furusyo
Eiichi Ogawa
Hiroaki Ikezaki
Tsuyoshi Ihara
Takeo Hayashi
Mosaburo Kainuma
Masayuki Murata
Jun Hayashi
Publication date
01-02-2013
Publisher
Springer US
Published in
Endocrine / Issue 1/2013
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9688-x

Other articles of this Issue 1/2013

Endocrine 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.